| Vanessa S Wong, MD | |
|
95 390 Kuahelani Ave, Mililani, HI 96789 | |
| (808) 627-3200 | |
| (808) 623-8782 |
| Full Name | Vanessa S Wong |
|---|---|
| Gender | Female |
| Speciality | Family Medicine |
| Location | 95 390 Kuahelani Ave, Mililani, Hawaii |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1497726772 | NPI | - | NPPES |
| 235812 | Other | HI | HMSA |
| 53035401 | Medicaid | HI |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | MD11843 (Hawaii) | Primary |
| Entity Name | Kokua Kalihi Valley Comprehensive Family Services |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1114074622 PECOS PAC ID: 0547258741 Enrollment ID: O20190401001159 |
News Archive
Three Indiana University professors have received $2.1 million to develop a computational model of acetaminophen-induced liver failure - the leading cause of liver failure in the United States - by using advanced microscopic and computational technologies that allow scientists to see into the liver of a living animal.
Results of a phase one trial show that an investigational topical drug, resiquimod gel, causes regression of both treated and untreated tumor lesions and may completely remove cancerous cells from both sites in patients with early stage cutaneous T cell lymphoma (CTCL) - a rare type of non-Hodgkin lymphoma that affects the skin.
Aerpio Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on advancing innovative therapies for vascular diseases, today announced that it has dosed the first patient in a Phase 2 trial evaluating AKB-9778, a Tie2 activator, alone and in combination with ranibizumab (Lucentis) for the treatment of diabetic macular edema (DME). AKB-9778 is a first-in-class inhibitor of human protein tyrosine phosphatase beta (HPTPβ) that activates the Tie2 pathway to promote vascular stability, preventing abnormal blood vessel growth and vascular leak.
Secretary of State Hillary Rodham Clinton is set to announce on Thursday morning a five-year initiative among the U.S. and five other countries - Canada, Sweden, Mexico, Ghana and Bangladesh - to cut pollutants that contribute to global warming, the Washington Post reports.
Michigan Accelerator Fund I, L.P., today announced the formation of the community's first venture capital fund formed specifically to support early stage life science and technology companies: the Michigan Accelerator Fund 1 (MAF1).
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Vanessa S Wong, MD 95 390 Kuahelani Ave, Mililani, HI 96789 Ph: (808) 627-3200 | Vanessa S Wong, MD 95 390 Kuahelani Ave, Mililani, HI 96789 Ph: (808) 627-3200 |
News Archive
Three Indiana University professors have received $2.1 million to develop a computational model of acetaminophen-induced liver failure - the leading cause of liver failure in the United States - by using advanced microscopic and computational technologies that allow scientists to see into the liver of a living animal.
Results of a phase one trial show that an investigational topical drug, resiquimod gel, causes regression of both treated and untreated tumor lesions and may completely remove cancerous cells from both sites in patients with early stage cutaneous T cell lymphoma (CTCL) - a rare type of non-Hodgkin lymphoma that affects the skin.
Aerpio Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on advancing innovative therapies for vascular diseases, today announced that it has dosed the first patient in a Phase 2 trial evaluating AKB-9778, a Tie2 activator, alone and in combination with ranibizumab (Lucentis) for the treatment of diabetic macular edema (DME). AKB-9778 is a first-in-class inhibitor of human protein tyrosine phosphatase beta (HPTPβ) that activates the Tie2 pathway to promote vascular stability, preventing abnormal blood vessel growth and vascular leak.
Secretary of State Hillary Rodham Clinton is set to announce on Thursday morning a five-year initiative among the U.S. and five other countries - Canada, Sweden, Mexico, Ghana and Bangladesh - to cut pollutants that contribute to global warming, the Washington Post reports.
Michigan Accelerator Fund I, L.P., today announced the formation of the community's first venture capital fund formed specifically to support early stage life science and technology companies: the Michigan Accelerator Fund 1 (MAF1).
› Verified 9 days ago
Dr. Corey C Chinn, MD Family Medicine Medicare: Medicare Enrolled Practice Location: 95-390 Kuahelani Ave, Mililani, HI 96789 Phone: 808-586-2890 | |
Anna Tamai, M.D. Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 95-390 Kuahelani Avenue, The Physician Center, Mililani, HI 96789 Phone: 808-627-3230 | |
Kana Maeji, DO Family Medicine Medicare: Medicare Enrolled Practice Location: 95-390 Kuahelani Ave, Mililani, HI 96789 Phone: 808-627-3255 | |
Dr. Steven A Hankins, M.D., M.P.H., M.T.S. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 95-390 Kuahelani Ave, Physician Center Mililani, Mililani, HI 96789 Phone: 808-627-3200 Fax: 808-627-3262 | |
Nataliya V Holmes, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 95-1249 Meheula Pkwy, Mililani, HI 96789 Phone: 808-625-6444 | |
Dr. Melanie Moanikeala Payanal, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 95-390 Kuahelani Ave, Mililani, HI 96789 Phone: 808-627-3230 | |
Dr. Carrie Suzanne Marshall, M.D. Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 95-390 Kuahelani Ave, Mililani, HI 96789 Phone: 808-627-3230 |